Observational Cohort To Assess Therapeutic Efficacy And Emergence Of HIV Drug Resistance Following Initiation Of Tenofovir-Lamivudine-Dolutegravir (TLD) For First- Or Second-Line ART

AIDS Clinical Trials Group0 个研究点目标入组 100 人开始时间: 2020年5月28日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Inclusion Criteria
•1.Receiving care at a PEPFAR-supported site.
•2 Documentation of HIV-1 infection acceptable to the local PEPFAR-supported
•program to allow antiretroviral (ARV) treatment to be initiated or continued.
•3 Age more than or equal to 10 years.
•4 Ability and willingness of participant or legal guardian/representative to provide
•informed consent to participate in the study.
•5 Expectation that the participant will receive care within the local PEPFARsupported
•program and will be able to be followed for study evaluations for at
•least 6 months and ideally for 36 months.

•Exclusion Criteria
•1. Weight less than 30 kg.
•2 For participants already on ART in Groups 1, 2, and 3, known to have had an
•ART interruption encompassing the entire 14 day window (=14 consecutive days)
•immediately prior to study entry.
•3 For Group 3, if a participant is already taking TLD at the time of study entry, HIV-
•1 RNA >1000 copies/mL within the past 9 months while taking TLD with no
•subsequent HIV-1 RNA =1000 copies/mL.
•4 Prior enrollment in any group in this study.
•5 For Group 3 participants, already on concomitant TLD and RIF-containing TB
•treatment prior to study entry.

发起方

AIDS Clinical Trials Group